AstraZeneca and Valeant to partner up on psoriasis drug brodalumab
AstraZeneca has entered into a collaboration agreement with Valeant Pharmaceuticals International under which it will grant an exclusive licence for Valeant to develop and commercialise psoriasis drug brodalumab.
AstraZeneca
12,026.00p
17:14 25/04/24
FTSE 100
8,078.86
17:14 25/04/24
FTSE 350
4,434.34
17:09 25/04/24
FTSE All-Share
4,387.94
16:49 25/04/24
Pharmaceuticals & Biotechnology
22,750.48
17:09 25/04/24
Under the terms of the agreement, Valeant will make an upfront payment to AstraZeneca of $100m, additional pre-launch milestones of up to $170m and further sales-related payments of up to $175m following launch. After approval, AstraZeneca and Valeant will share profits.
Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Under the terms of the deal, Valeant will hold the exclusive rights to develop and commercialise brodalumab globally, except in Japan and certain other Asian countries where the rights are held by Kyowa Hakko Kirin Co. Ltd under a prior arrangement with Amgen Inc, which is the originator of brodalumab.
AstraZeneca said Valeant will assume all development costs associated with the regulatory approval for brodalumab.
Regulatory submission in US and EU for brodalumab in moderate-to-severe psoriasis is planned for the fourth quarter of 2015.
Astra’s chief executive officer Pascal Soriot said: “Our agreement will help to bring brodalumab to patients with psoriasis who need new treatment options through Valeant's expert focus on dermatology."